Purpose: To assess the efficacy of topical 1.5% azithromycin in the treatment of mo derate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. Methods: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followedup for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eyefriendly soap twice daily. Results: Patients in both groups tolerated the treatment with minimal irritation. A signi ficant improvement in signs and symptoms was noted at the one week fol lowup visit. Group II showed a more pronounced and longerlasting improvement that persisted after three months of followup. Conclusion: Topical 1.5% azithromycin ophthalmic solution is an effective treat ment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the threeday protocol with no significant relapse until three months of followup.
INTRODUCTION
Blepharitis is a common disease of the eyelids. It is characterized by redness, itching, and greasy and crusty eyelashes. Anterior blepha ritis affects the anterior lamella of the eyelids, while posterior blepha ritis affects the posterior lamella and is due to dysfunction of the mei bomian glands with turbid secretions, plugging of the meibomian ori fices, and telangiectasia. Blepharitis is typically chronic in nature and is often associated with chalazion, acne rosacea, and dry eyes (1) . Chronic blepharitis appears to be a multifactorial disease, with in flammatory and mechanical components, in addition to a low gra de infectious component. It is commonly associated with ocular pathogens such as coagulase negative staphylococci, Staphylococcus epidermidis, and Staphylococcus aureus; all of which are normal flora of the eyelid margin (14) . Due to the relapsingremitting nature of the disease, the standard treatment regimen is usually for lifetime. It consists of local lid hygiene and eyelid scrubs with warm compresses. Adjunctive treatments include topical antibiotics (usually erythromy cin or fusidic acid), systemic antibiotics (usually tetracyclines in diffe ring doses), topical corticosteroids, and tear replacement therapy. In severe deformation and scarring, none of the previously mentioned treatment options work. Antibiotics decrease the bacterial load, while corticosteroids relieve the inflammation. However, results are not very satisfying to both patients and physicians, with a low patient com pliance and a high recurrence rate after stopping treatment.
Recently, topical azithromycin, a second generation macrolide, has been proposed as a novel treatment, since it appears to be su perior to erythromycin ointment and to warm compresses alone in the treatment of blepharitis (57) . Its advantages reside in a broadsp ec trum antibacterial profile, antiinflammatory properties, a high tissue distributionparticularly in the conjunctiva and eyelids and an in vivo prolonged postantibiotic effect (812) . Its antibacterial activity is di rected against many grampositive and gramnegative bacteria, in addition to atypical bacteria. It binds reversibly to the 50S subunit of the bacterial ribosome and inhibits RNAdependent protein synthe (13) . Azithromycin was studied in bacterial conjunctivitis and proved to be both effective and safe with good patient tolerance (14, 15) . The purpose of the present study is to determine the efficacy of topical azithromycin 1.5% ophthalmic solution combined with eye lid hygiene in the treatment of patients with moderate to severe anterior and/or posterior blepharitis and to compare two different modalities of administration: a threeday regimen versus a prolonged onemonth regimen.
METHODS
A randomized prospective study was performed between July, 2010 and December, 2010 in two different settings: The Ophthalmic Consultants of Beirut, a private practice affiliated with the Lebanese American University, and the Ophthalmology Department of Hotel Dieu de France Hospital (Saint Joseph University), Beirut, Lebanon. This study was approved by the ethics committee/Investigational Review Board of the Ophthalmic Consultants of Beirut and was car ried out in compliance with the Declarations of Helsinki following good clinical practice guidelines.
Sixtyseven patients with diagnosis of moderate to severe an terior and/or posterior chronic blepharitis were enrolled in the stu dy and followedup for a period of 3 months. Inclusion criteria included pa tients above the age of 18 years presenting to either the Ophthal mic Consultants of Beirut or the Ophthalmology Department of Ho telDieu de France between July, 2010 and December, 2010 with signs of itching, burning, tearing, foreignbody sensation or blurry vision and signs of redness, collarettes, telangiectasia or meibomian gland dysfunction (MGD). Exclusion criteria included re fusal of patients to consent for participating in the study, gross lid structural abnorma lity, and corneal scarring. The aim of the study and the experimental nature of azithromycin in treating blepharitis were explained to all pa tients. All patients signed an informed consent before participating in the study. Patients were seen and assessed upon diagnosis, and at one week, one month and three months after starting treatment. At each visit, patients were asked about the presence of the following symptoms: itching, burning, tearing, foreign body sensation and blu rry vision. The presence of any of these symptoms was graded as specified in table 1. On slit lamp examination, clinical signs of ble pharitis were identified. These included: lid collarettes, lid redness and swelling with or without telangiectasia, and MGD consisting of plugging of the meibomian glands (MG) orifices and altered MG secretions. One ophthalmologist examined and graded the signs in all patients. Both eyes of each patient were examined, but only the worse eye of each patient was included in statistical analysis. The same ophthalmologist graded the signs on subsequent visits. This ophthalmologist was blinded to the treatment protocol assigned to each patient but was aware that patients were, or currently are still on treatment.
The scoring system used is outlined in table 1. It was adapted from the International Ocular Inflammation Society (IOIS) grading of signs and symptoms (16) and the grading system of the initial study by Luchs in 2008 (6) . Patients were randomly assigned into 2 groups. Randomization was done using a computergenerated number sequence: if the number was even, the patient was assigned to group I; if the number was odd, the patient was assigned to group II. Randomization was not done by the treating physician, but by a third year ophthalmology resident.
Exclusion criteria were: lid structural abnormalities, inflammatory or infectious keratitis or iridocyclitis, penetrating intraocular surgery during the past three months, ocular surface surgery (including re fractive surgery and pterygiectomy) in the past six months, a known hypersensitivity to azithromycin or any other macrolide antibiotic, and the use of any of the following medications within one month of the study: ocular or oral antibiotics, topical or systemic steroids, ocular nonsteroidal antiinflammatory drugs, ocular cyclosporine and ocular antihistamine and/or mast cell stabilizers. Pregnant and lactating women were also excluded. Women of childbearing poten tial were required to use a contraceptive method.
All patients were treated with lid hygiene with an eyefriendly soap at bedtime (Baby Johnson Shampoo, Johnson&Johnson), and five minutes of warm compresses twice a day. Group I patients were trea ted with preservativefree, unitdose, topical 1.5% azithromycin (Azyter ® , Laboratoires Thea, France) twice a day for three days, and Group II patients were treated with the same drug, twice a day for three days then once at bedtime for the rest of the month. All groups were instructed to continue warm compresses and lid hygiene for life.
Statistical analysis was done using the Statistical Program for So cial Sciences (SPSS) version 13.0 software (SPSS Inc, Chicago, IL, USA). A p value ≤ 0.05 was considered statistically significant. A Wilcoxon signed rank test (WSR) was used to compare symptoms mean severi ty score and clinical signs mean severity score variation from baseline and between consecutive visits.
RESULTS
Seventy Caucasian patients were diagnosed with anterior and/or posterior blepharitis between July, 2010 and December, 2010. Thir tyfour patients were assigned to group I, and 36 patients to group II. One patient in group I discontinued prematurely due to allergic reac tion, and 2 patients in group II discontinued due to continuous irritation. Consequently, sixty seven patients were treated according to protocol and followedup for a period of 3 months (33 patients in group I, and 34 patients in group II).
Patients' demographics are presented in table 2. The study inclu ded 32 male patients (48%) and 35 female patients (52%). Patients' age varied from 18 to 82 years with a mean of 55.0 ± 15.1 years. The two groups were comparable in terms of gender and age (p=0.92 and p=0.15, respectively).
Symptoms' mean severity scores at baseline were 2.7 in group I and 2.9 in group II (p=0.35). The score improved significantly after one (16) **= grading system identical to the one used in the 2008 study by Luchs comparing azithromycin to warm compresses (6) . The plugging of meibomian glands (MG) orifices score and the MG secretions score were added later on to determine a total meibomian glands dysfunction (MGD) score. This was done for a reporting purpose week of treatment to 1.6 and 1.3 respectively (p=0.01 and 0.01 respec tively). No further improvement or worsening was noted throughout the three months followup period, in both groups (Table 3 , with a p value >0.1 between all the consecutive visits).
Clinical signs' mean severity scores are depicted in table 4 and in figure 1. Lid collarettes scored 2.2 in group I vs. 2.1 in group II at baseline (p=0.67). Lid redness/swelling scored 1.3 in group I vs. 1.5 in group II at baseline (p=0.32), and meibomian glands dysfunction (MGD) scored 3.9 in group I vs. 4.1 in group II at baseline (p=0.36).
Concerning lid collarettes, the severity score significantly impro ved after one week of treatment in both groups with no further change at the onemonth and threemonths followup (with a p va lue >0.1 between all the consecutive visits). Concerning lid redness/ swelling, the severity score significantly improved at one week in both groups, with no further change at the onemonth visit (with a p value >0.1 between all the consecutive visits). A relapse occurred at three months in group I (p=0.07) while the initial improvement was maintained in group II (p=0.01). Group II also yielded better results in terms of MGD with a longerlasting improvement that persisted at the three month' followup (p=0.01). Patients in group I had a worse ning in MGD at the onemonth (p=0.06) and threemonth followup visits (p=0.11). A comparison of the change in clinical signs between both groups is reported in Table 5 . At 3 months, patients in group I presented worse results when comparing the score change from baseline in lid redness/swelling (p=0.04) and MGD (p=0.03).
DISCUSSION
Chronic blepharitis is a worldwide public health problem due to its prevalence, its chronicity, and the difficulty in treating it. Although no definitive epidemiological data exist in the literature, clinicians agree that its prevalence is very high in the routine ophthalmology consultation. In one study, ophthalmologists and optometrists re port a blepharitis rate of 37% and 47% respectively in their clinical prac tice (17) . As we previously stated, many treatment options are used to ma nage this multifactorial resistant disease but none has proved to be curative. Recurrence is very high and lifetime treatments are usually required.
MGD, the main component of posterior blepharitis, is a chronic, diff use abnormality of the meibomian glands, commonly characte rized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease (18) . In this prospective study, we treated all patients with warm com presses and lid hygiene. Adjunctive treatment consisting of 1.5% azi thromycin (Azyter ® ) was used in two different modalities: A threeday protocol (group I) versus a onemonth protocol (group II). The study started in summer and stopped before springtime which factors out the effect of pollen -which has also been shown to worsen MGD.
Bias was kept to a minimum by randomization, and by the fact that one blinding ophthalmologist assessed signs unanimously in all patients. This ophthalmologist was also not involved in the direct treatment of these patients.
As expected by randomization, both groups were comparable at the beginning of the study with no statistically significant difference between them in terms of age, gender and all signs and symptoms' severity scores. Both groups had a sustained improvement in symp toms with severity scores significantly better after only one week of starting treatment. The decrease in symptomatology was main tained all the way through the threemonth followup period with no observed trend toward regression, but this information may be biased considering that patients knew they had received treatment. Concerning clinical signs of blepharitis, significant and rapid impro vement occurred at one week in all clinical signs. However, progres sive deterioration was observed in group I, with lid redness/swelling and MGD presenting a tendency to recur. Group II showed the best results: improvement in lid redness/swelling and signs of posterior blepharitis (plugging and quality of meibomian glands secretions) was more pronounced and longerlasting with no trends toward regression at the threemonth followup visit. All patients strictly adhered to the followup schedule that was set. Patients were asked to followup as early as one week after starting the treatment to insist on compliance, especially concerning lid hygiene which might be a bothersome maneuver on the long run.
Former studies demonstrated the high efficacy of azithromycin in bacterial conjunctivitis, based on interesting pharmacokinetics that emphasizes its high conjunctival concentration and its prolonged postadministration effect. The azithromycin molecule is extremely lipophilic, a property that makes it more difficult to formulate into an aqueous solution for topical application, but makes its penetration into conjunctival cells easier. In fact, azithromycin incorporates itself into conjunctival cells and has been found in conjunctival biopsies several days after the last drop (815) . As described previously (813) , the effect of azithromycin on blepha ritis is dual: both antibacterial (antibiotic effect ) and antiinflammatory (by DNA modification). Azithromycin affects neutrophils through me diation of apoptosis, migration, chemotactic activity, and phagocytic function. It is an indirect antioxidant and decreases production of nitric oxide, prostaglandin E2, and proinflammatory cytokines In Azyter ® , azithromycin is bound to lipid molecules in solution, thus facilitating its binding to the mucinous and conjunctival cells of the palpebral (and bulbar) conjunctiva (22) . Although no polycarbophil drug delivery system is incorporated in Azyter ® , it achieved satisfac tory results in blepharitis in comparison to the studies performed on AzaSite ® . In the study by Haque et al., treatment with AzaSite ® for 28 days (twice a day on days 1 and 2 and once a day on days 328) found similar results of significantly improving meibomian gland dys function. This lasted at least up to the onemonth posttreatment followup. Patients were prohibited from using warm compresses in this study (23) . Similar results were also found by Opitz and Tyler fol lowing a 30day 1% azithromycin treatment protocol (twice a day for two days, then every evening for a total of 30 days) (24) . Foulks et al. studied the spectroscopic behavior of the meibomian glands' lipids and demonstrated the beneficial effect of topical therapy with 1% azithromycin on the quality of meibomian glands' secretions. After a onemonth treatment with AzaSite ® (1 drop twice daily for 2 days then once daily) the lipid properties of the meibomian secretions were restored toward normal (25) . Thus, an important reason why azi thromycin works in blepharitis is because it improves the overall quality of meibum by changing the 50s ribosomal subunit.
There are no studies comparing AzaSite ® to Azyter ® concentra tions in human ocular tissues. A head to head study comparing the two drugs is needed to see if there is a real difference between the two formulations in terms of efficacy and recurrence rate in the treat ment of blepharitis. A one month treatment with 1.5% azithromycin was well tole rated by the patients with minimal irritation. It yielded better resu lts than the threeday protocol recommended by the company for the treatment of bacterial conjunctivitis (22) . This is especially true for the posterior signs of the disease with no recurrence at the three months followup visit. However, we believe that recurrence will eventually occur because blepharitis is an incurable chronic disease that warrants continuous care. We obviously need a longer fol lowup period to assess the exact timing of relapse after this onemonth azithromycin regimen. Knowing the extent of the remission period is important for future recommendations, as patients could then take a fixed number of courses per year and be diseasefree throughout the whole year.
CONCLUSION
Azithromycin 1.5% ophthalmic solution appears to be an effecti ve treatment option for chronic blepharitis. It exerts a beneficial effect on meibomian gland function with an improvement in the quality of lipid secretions.
In moderate to severe blepharitis, a one month treatment with 1.5% azithromycin (twice daily for three days then once at bedtime for the rest of the month) is safe and well tolerated and resulted in more improvement than a threeday protocol, with a more pronounced and longerlasting effect on signs of posterior blepharitis.
